Skip to main content

Table 5 Multinomial logistic regression analysis by treatment category

From: Impact of a protein-based assay that predicts prostate cancer aggressiveness on urologists’ recommendations for active treatment or active surveillance: a randomized clinical utility trial

  Correct Treatment Physician counsels patient on all treatment options No Prostate Cancer Treatment
  Odds ratio 95% Confidence Interval P-value Odds ratio 95% Confidence Interval P-value Odds ratio 95% Confidence Interval P-value
Intervention 0.94 (0.47,1.82) 0.860 0.57 (0.338,1.00) 0.050 0.99 (0.56,1.72) 0.960
Interaction Round with Study Arm 2.84 (1.39,5.82) 0.004 2.72 (1.47, 5.05) 0.001 0.98 (0.50,1.89) 0.946
Onsite robotics capacity 0.87 (0.51,1.49) 0.608 0.92 (0.59,1.44) 0.716 0.78 (0.49,1.26) 0.318
More than 20 prostate cancer patients per week 0.64 (0.35,1.15) 0.138 0.43 (0.26,0.70) 0.001 0.56 (0.33,0.95) 0.031
More than 100 urology patients per week 1.14 (0.64,2.03) 0.652 1.10 (0.69,1.78) 0.682 1.36 (0.81,2.26) 0.243
Greater than 50% public payors 0.99 (0.97,1.01) 0.400 1.00 (0.98,1.02) 0.889 1.00 (0.98,1.02) 0.768
Age over 40 1.02 (0.99,1.05) 0.217 1.01 (0.98,1.04) 0.435 1.05 (1.02,1.08) 0.000
Physician-owned practice 1.21 (0.49,2.95) 0.678 0.82 (0.41,1.64) 0.572 1.20 (0.55,2.64) 0.648
Constant 0.56 (0.05,6.03) 0.636 4.27 (0.63,28.78) 0.136 0.38 (0.05,2.92) 0.354
  1. Incorrect treatment is the baseline treatment mode. Model also controls for CPV case type